R E Buckingham
Overview
Explore the profile of R E Buckingham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buckingham R, Hanna A
Diabetes Obes Metab
. 2008 Mar;
10(4):312-28.
PMID: 18333890
Thiazolidinediones (TZDs) are relatively new agents for the treatment of type 2 diabetes. They act as agonists at the PPAR-gamma nuclear receptor and their therapeutic effects include decreased insulin resistance...
2.
Moore G, Pickavance L, Briscoe C, Clapham J, Buckingham R, Wilding J
Diabetes Obes Metab
. 2008 Feb;
10(3):251-63.
PMID: 18269641
Aim: Consumption of a palatable diet can induce hyperphagia, leading to weight gain (dietary obesity) and insulin resistance in rats. Thiazolidinediones (TZDs) can also induce hyperphagia in rats but conversely...
3.
Hockings P, Changani K, Saeed N, Reid D, Birmingham J, OBrien P, et al.
Diabetes Obes Metab
. 2003 Jun;
5(4):234-43.
PMID: 12795656
Aim: This study aimed to chart the time course and durability of the effects of rosiglitazone, a potent thiazolidinedione-based peroxisome proliferator-activated receptor gamma agonist, on hepatic steatosis and intramyocellular lipid...
4.
Buckingham R, Arch J, Briscoe C, Jenkins O, Tadayyon M
Diabetes Obes Metab
. 2002 Mar;
3(6):435-42.
PMID: 11903416
Aim: To clarify whether centrally delivered leptin can access the circulation and to determine to what extent the effects of i.c.v. h-leptin and m-leptin on body weight and plasma corticosterone...
5.
Yue Tl T, Chen J, Bao W, Narayanan P, Bril A, Jiang W, et al.
Circulation
. 2001 Nov;
104(21):2588-94.
PMID: 11714655
Background: Diabetes is associated with increased risk of mortality as a consequence of acute myocardial infarction. This study determined whether rosiglitazone (ROSI) could reduce myocardial infarction after ischemia/reperfusion injury. Methods...
6.
Pickavance L, Buckingham R, Wilding J
Diabetes Obes Metab
. 2001 Jun;
3(3):171-80.
PMID: 11412281
Aim: We investigated whether pair-feeding to prevent hyperphagia would potentiate the insulin-sensitizing effect of rosiglitazone in chow-fed and insulin-resistant dietary obese rats, and studied the role of leptin and hypothalamic...
7.
Finegood D, McArthur M, Kojwang D, Thomas M, Topp B, Leonard T, et al.
Diabetes
. 2001 May;
50(5):1021-9.
PMID: 11334404
The evolution of diabetes in the male leptin receptor-deficient (fa/fa) Zucker diabetic fatty (ZDF) rat is associated with disruption of normal islet architecture, beta-cell degranulation, and increased beta-cell death. It...
8.
Smith S, LISTER C, Toseland C, Buckingham R
Diabetes Obes Metab
. 2001 Feb;
2(6):363-72.
PMID: 11225966
Aim: To investigate the potential of rosiglitazone, a highly potent agonist at the nuclear peroxisome proliferator activated receptor-gamma (PPAR-gamma), to prevent the development of diabetes in the Zucker diabetic fatty...
9.
Buckingham R, Tadayyon M, Arch J
Int J Obes Relat Metab Disord
. 2000 Sep;
24 Suppl 2:S127-8.
PMID: 10997629
No abstract available.
10.
Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats
Arch J, Buckingham R, Tadayyon M
Obes Res
. 2000 Aug;
8(4):317-23.
PMID: 10933308
Objective: To investigate whether chronic administration of the long-acting glucagon-like peptide-1 receptor agonist exendin-4 can elicit sustained reductions in food intake and body weight and whether its actions require an...